तुलना करने के लिए मीट्रिक्स | 688759 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध688759पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −37.1x | 21.5x | −0.2x | |
PEG अनुपात | - | −0.72 | 0.00 | |
क़ीमत/बुक | 4.7x | 2.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 5.5x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | 208.1% | 93.6% | 64.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.0% | 9.7% | अनलॉक करें |
BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease; BEBT-809, a GPR75 pathway inhibitor for metabolic disease; and BEBT-508, a small nucleic acid drug. The company was founded in 2012 and is based in Guangzhou, China.